Apricus Biosciences

Apricus Biosciences

Employees:
20
Market Cap:
$17.31 million
Revenue:
$5.88 million
5 Year Trend:
7.0%
Net Income:
$-7.42 million
NASDAQ:
APRI

Apricus Biosciences, Inc. is a San Diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus Biosciences' first product, Vitaros®, has been approved in Europe and Canada for the treatment of erectile dysfunction Other compounds in development include: low testosterone, rheumatology, sexual dysfunction, pain, Until September 10, 2010, when it formally changed its name, Apricus Biosciences, Inc. (NASDAQ: APRI) had been operating in the pharmaceutical industry since 1995 under the name NexMed, Inc. Wikipedia

Apricus Biosciences
Employees:
20
Market Cap:
$17.31 million
Revenue:
$5.88 million
5 Year Trend:
7.0%
Net Income:
$-7.42 million
NASDAQ:
APRI

Apricus Biosciences, Inc. is a San Diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus Biosciences' first product, Vitaros®, has been approved in Europe and Canada for the treatment of erectile dysfunction Other compounds in development include: low testosterone, rheumatology, sexual dysfunction, pain, Until September 10, 2010, when it formally changed its name, Apricus Biosciences, Inc. (NASDAQ: APRI) had been operating in the pharmaceutical industry since 1995 under the name NexMed, Inc. Wikipedia